Pliant Therapeutics Inc. (PLRX)
Pliant Therapeutics Statistics
Share Statistics
Pliant Therapeutics has 61.24M shares outstanding. The number of shares has increased by 1.51% in one year.
| Shares Outstanding | 61.24M |
| Shares Change (YoY) | 1.51% |
| Shares Change (QoQ) | 0.63% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 52.99M |
| Failed to Deliver (FTD) Shares | 270 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 7.54M, so 12.39% of the outstanding shares have been sold short.
| Short Interest | 7.54M |
| Short % of Shares Out | 12.39% |
| Short % of Float | 14% |
| Short Ratio (days to cover) | 13.44 |
Valuation Ratios
The PE ratio is -3.79 and the forward PE ratio is -2.78. Pliant Therapeutics's PEG ratio is -0.14.
| PE Ratio | -3.79 |
| Forward PE | -2.78 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 2.62 |
| P/FCF Ratio | -5 |
| PEG Ratio | -0.14 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Pliant Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.91, with a Debt / Equity ratio of 0.1.
| Current Ratio | 10.91 |
| Quick Ratio | 10.91 |
| Debt / Equity | 0.1 |
| Debt / EBITDA | -0.13 |
| Debt / FCF | -0.19 |
| Interest Coverage | -10.83 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.23M |
| Employee Count | 171 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -90.93% in the last 52 weeks. The beta is 1.47, so Pliant Therapeutics's price volatility has been higher than the market average.
| Beta | 1.47 |
| 52-Week Price Change | -90.93% |
| 50-Day Moving Average | 4.2 |
| 200-Day Moving Average | 10.7 |
| Relative Strength Index (RSI) | 26.23 |
| Average Volume (20 Days) | 2.7M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -228.37M |
| Net Income | -210.3M |
| EBITDA | -228.37M |
| EBIT | -189.22M |
| Earnings Per Share (EPS) | -3.47 |
Balance Sheet
The company has 71.19M in cash and 29.98M in debt, giving a net cash position of 41.21M.
| Cash & Cash Equivalents | 71.19M |
| Total Debt | 29.98M |
| Net Cash | 41.21M |
| Retained Earnings | -710.05M |
| Total Assets | 396.95M |
| Working Capital | 329.05M |
Cash Flow
In the last 12 months, operating cash flow was -155.5M and capital expenditures -3.85M, giving a free cash flow of -159.35M.
| Operating Cash Flow | -155.5M |
| Capital Expenditures | -3.85M |
| Free Cash Flow | -159.35M |
| FCF Per Share | -2.63 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PLRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for PLRX is $3, which is 127.3% higher than the current price. The consensus rating is "Hold".
| Price Target | $3 |
| Price Target Difference | 127.3% |
| Analyst Consensus | Hold |
| Analyst Count | 10 |
Scores
| Altman Z-Score | -2.71 |
| Piotroski F-Score | 1 |